Reviewing Clinical Translation of Treg Therapies in Transplantation & Beyond
9:00 am - Wednesday 24th March 2027
- Reviewing comprehensive findings from the completed clinical trial in transplanted children to identify key safety, feasibility, and translational learnings for the advancement of Treg therapies
- Highlighting the first allogeneic use of the therapy through compassionate use to explore the potential of donor-independent Treg approaches and their implications for broader patient access
- Discussing recent company progress, including manufacturing scale-up and expanded dose generation capabilities, to support the continued development of next-generation Treg therapies